التفاصيل البيبلوغرافية
| العنوان: |
doi:10.1155/2012/578641 Review Article Biological Therapy in Systemic Lupus Erythematosus |
| المؤلفون: |
Mariana Postal, Lilian Tl Costallat |
| المساهمون: |
The Pennsylvania State University CiteSeerX Archives |
| المصدر: |
ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/93/5b/Int_J_Rheumatol_2012_Jan_30_2012_578641.tar.gz |
| سنة النشر: |
2011 |
| المجموعة: |
CiteSeerX |
| الوصف: |
Copyright © 2012 Mariana Postal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic lupus erythematosus (SLE) is a prototypic inflammatory autoimmune disorder characterized by multisystem involvement and fluctuating disease activity. Symptoms range from rather mild manifestations such as rash or arthritis to life-threatening endorgan manifestations. Despite new and improved therapy having positively impacted the prognosis of SLE, a subgroup of patients do not respond to conventional therapy. Moreover, the risk of fatal outcomes and the damaging side effects of immunosuppressive therapies in SLE call for an improvement in the current therapeutic management. New therapeutic approaches are focused on B-cell targets, T-cell downregulation and costimulatory blockade, cytokine inhibition, and the modulation of complement. Several biological agents have been developed, but this encouraging news is associated with several disappointments in trials and provide a timely moment to reflect on biologic therapy in SLE. 1. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/zip |
| اللغة: |
English |
| العلاقة: |
http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.271.2186Test |
| حقوق: |
Metadata may be used without restrictions as long as the oai identifier remains attached to it. |
| رقم الانضمام: |
edsbas.69EB8F31 |
| قاعدة البيانات: |
BASE |
